Johnson & Johnson halts late-stage E.coli vaccine trial after poor results

New York Post

Lean Right

Factuality

Ownership

Johnson & Johnson halts late-stage E.coli vaccine trial after poor results

Pharmaceutical giants Johnson & Johnson and Sanofi have stopped a late-stage clinical trial for their experimental E.coli vaccine.

The Straits Times

Lean Right

Factuality

Ownership

J&J, Sanofi stop E.coli vaccine trial due to low effectiveness

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by the E.coli bacteria due to a lack of sufficient efficacy, the companies said on Thursday.

Le Figaro

Lean Right

Factuality

Ownership

The French pharmaceutical giant Sanofi announced on Thursday that a clinical trial of a vaccine candidate "was not effective enough to prevent invasive E. coli infections".

contagionlive.com

Factuality

Ownership

Investigational E coli Vaccine Does Not ‘Demonstrate Sufficient Efficacy’ in Phase 3 Study

As a result of an independent committee’s determination, the study has been discontinued.

Clinical Trials Arena

Factuality

Ownership

J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results

The company said it will stop the Phase III trial of E.Coli vaccine ExPEC after interim results found it failed to demonstrate efficacy.The post J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results appeared first on Clinical Trials Arena.

Pharmaphorum

Factuality

Ownership

Sanofi, J&J abandon trial of E coli vaccine after poor data

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by E coli looks all but defunct after they abandon a phase 3 trial.